Alex Kim, MA., Elevar Therapeutics, Chief Executive Officer
Mr. Kim has 30 years experience in the pharmaceutical industry. Mr. Kim’s experience includes executive management, business development, product and technology licensing, strategic planning, fund raising and M&A activity.
Soo Whan Choi, PhD., Elevar Therapeutics, Chief Strategy Officer
Dr. Choi has over 25 years experience in the pharmaceutical industry. He is a successful corporate leader combining a strong background in business development, fundraising, M&A activity, and operations.
Mr. Gueth joined the Board of Directors as an independent member in 2018. He was previously a Managing Director of Burrill Securities, and since October 2014 has been serving as Managing Director of EVOLUTION Life Science Partners.
In Keun Jang, PhD., HLB, Managing Director
Dr. Jang has more than 15 years of experience in the pharmaceutical and medical device industry. His experience includes product and business development, market and company analysis, and project management.
He leads the Bio Strategic Planning Team for the HLB Group.
Dong Gun Kim, J.D., Elevar Therapeutics, Chief Strategy Officer
Mr. Dong Gun Kim joined the Board in 2020. He currently serves as both Chief Strategy Officer of Elevar and President of HLB. Prior to joining Elevar/HLB, Mr. Kim spent more than 30 years as a specialist in M&A, corporate finance and investment management at leading corporations and professional firms (law, investment banking and private equity) both in the U.S. and Korea. Mr. Kim has an A.B. in Physics from Harvard College and a J.D. from Harvard Law School.
Yang Gon Jin, HLB, Chief Executive Officer
Mr. Jin joined the Board in 2020. He is Chief Executive Officer of HLB, which is Elevar’s parent company, and leads HLB Group as Chairman, bringing seasoned leadership and keen insights gained from a broad management background. He is committed to alleviating human disease and suffering by finding new treatments for patients with cancer and other illnesses throughout the world.